BIOMAT Database Logo BIOMAT Database Logo

Continuous infusion of amphotericin B deoxycholate for the treatment of life-threatening Candida infections. 2013

Seyedmojtaba Seyedmousavi, and Johan W Mouton, and Paul E Verweij, and David R Andes
1 Radboud University Nijmegen Medical Centre Nijmegen, The Netherlands and Nijmegen Institute for Infection, Inflammation and Immunity Nijmegen, The Netherlands.

UI MeSH Term Description Entries
D002177 Candidiasis Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed) Candida Infection,Moniliasis,Candida Infections,Candidiases,Infection, Candida,Moniliases
D003428 Cross Infection Any infection which a patient contracts in a health-care institution. Hospital Infections,Nosocomial Infections,Health Care Associated Infection,Health Care Associated Infections,Healthcare Associated Infections,Infection, Cross,Infections, Hospital,Infections, Nosocomial,Cross Infections,Healthcare Associated Infection,Hospital Infection,Infection, Healthcare Associated,Infection, Hospital,Infection, Nosocomial,Infections, Cross,Infections, Healthcare Associated,Nosocomial Infection
D003840 Deoxycholic Acid A bile acid formed by bacterial action from cholate. It is usually conjugated with glycine or taurine. Deoxycholic acid acts as a detergent to solubilize fats for intestinal absorption, is reabsorbed itself, and is used as a choleretic and detergent. Deoxycholate,Desoxycholic Acid,Kybella,Choleic Acid,Deoxycholic Acid, 12beta-Isomer,Deoxycholic Acid, 3beta-Isomer,Deoxycholic Acid, 5alpha-Isomer,Deoxycholic Acid, Disodium Salt,Deoxycholic Acid, Magnesium (2:1) Salt,Deoxycholic Acid, Monoammonium Salt,Deoxycholic Acid, Monopotassium Salt,Deoxycholic Acid, Monosodium Salt,Deoxycholic Acid, Sodium Salt, 12beta-Isomer,Dihydroxycholanoic Acid,Lagodeoxycholic Acid,Sodium Deoxycholate,12beta-Isomer Deoxycholic Acid,3beta-Isomer Deoxycholic Acid,5alpha-Isomer Deoxycholic Acid,Deoxycholate, Sodium,Deoxycholic Acid, 12beta Isomer,Deoxycholic Acid, 3beta Isomer,Deoxycholic Acid, 5alpha Isomer
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000666 Amphotericin B Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela. Amphocil,Amphotericin,Amphotericin B Cholesterol Dispersion,Amphotericin B Colloidal Dispersion,Fungizone
D000935 Antifungal Agents Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics

Related Publications

Seyedmojtaba Seyedmousavi, and Johan W Mouton, and Paul E Verweij, and David R Andes
Reply: continuous infusion of amphotericin B deoxycholate for the treatment of life-threatening Candida infections.
October 2013, American journal of respiratory and critical care medicine,
Seyedmojtaba Seyedmousavi, and Johan W Mouton, and Paul E Verweij, and David R Andes
Minimizing nephrotoxicity using continuous infusion of deoxycholate amphotericin B.
October 2014, The Pediatric infectious disease journal,
Seyedmojtaba Seyedmousavi, and Johan W Mouton, and Paul E Verweij, and David R Andes
Continuous infusion of amphotericin B deoxycholate: a cost-effective gold standard for therapy of invasive fungal infections?
January 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Seyedmojtaba Seyedmousavi, and Johan W Mouton, and Paul E Verweij, and David R Andes
continuous versus conventional infusion of amphotericin B deoxycholate: a meta-analysis.
January 2013, PloS one,
Seyedmojtaba Seyedmousavi, and Johan W Mouton, and Paul E Verweij, and David R Andes
Continuous infusion of amphotericin B deoxycholate: an innovative, low-cost strategy in antifungal treatment.
March 2011, Mycoses,
Seyedmojtaba Seyedmousavi, and Johan W Mouton, and Paul E Verweij, and David R Andes
Life-threatening adverse event after amphotericin B lipid complex treatment in a patient treated previously with amphotericin B deoxycholate.
April 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Seyedmojtaba Seyedmousavi, and Johan W Mouton, and Paul E Verweij, and David R Andes
Amphotericin B deoxycholate administered by continuous infusion: does the dosage make a difference?
April 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Seyedmojtaba Seyedmousavi, and Johan W Mouton, and Paul E Verweij, and David R Andes
Liposomal and Deoxycholate Amphotericin B Formulations: Effectiveness against Biofilm Infections of Candida spp.
December 2017, Pathogens (Basel, Switzerland),
Seyedmojtaba Seyedmousavi, and Johan W Mouton, and Paul E Verweij, and David R Andes
Sequential treatment of deep fungal infections with amphotericin B deoxycholate and amphotericin B colloidal dispersion.
July 1997, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
Seyedmojtaba Seyedmousavi, and Johan W Mouton, and Paul E Verweij, and David R Andes
Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study.
April 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Copied contents to your clipboard!